BOISE, ID — In the landscape of modern psychiatry, the intersection of aging, menopause, and long-term psychiatric prescription remains one of the most under-examined frontiers of public health. While much of the national conversation regarding the "opioid crisis" or "mental health epidemic" focuses on the youth or the working-age population, a silent cohort of older adults—specifically women traversing the hormonal shifts of menopause—finds itself increasingly ensnared in a web of long-term benzodiazepine and antidepressant use.
In a recent episode of the Mad in America podcast, host Brooke Siem, author of the antidepressant withdrawal memoir May Cause Side Effects, sat down with Marsha Zaritsky, a licensed mental health therapist and survivor of a decade-long struggle with prescription drugs. Their conversation illuminates a harrowing cycle of medical gaslighting, the physical devastation of "tolerance withdrawal," and the profound resilience required to reclaim a life from the grip of poly-drugging.
Main Facts: The Intersection of Hormones and Psychotropics
The core of Zaritsky’s narrative is a phenomenon all too common in primary care: the medicalization of menopause. What began as a prescription for insomnia—a hallmark symptom of hormonal transition—evolved into a ten-year dependency on Klonopin (clonazepam), a potent benzodiazepine.
Key facts emerging from Zaritsky’s experience include:
- The "Sleep" Trap: Benzodiazepines are frequently prescribed for sleep without adequate warnings regarding their high addictive potential and the difficulty of cessation.
- Tolerance Withdrawal: Patients often experience "withdrawal" symptoms while still taking the drug because the brain has adjusted to the dosage, leading to unexplained physical illness.
- Poly-drugging in Clinical Settings: Attempting to detox in a traditional rehab facility often results in "poly-drugging," where multiple new medications (antidepressants, antipsychotics, and anticonvulsants) are added to manage the acute withdrawal of the first drug.
- Hyperbolic Tapering: A scientific approach to tapering that involves decreasing doses by smaller and smaller amounts as the dose gets lower, acknowledging the non-linear way drugs affect brain receptors.
Zaritsky, a certified Internal Family Systems (IFS) therapist, represents a unique voice in this space—a clinician who was forced to become a patient, experiencing firsthand the systemic failures she was trained to navigate.
Chronology: A Decade of Decline and the Road to Recovery
The Initial Prescription (Circa 2010-2014)
Zaritsky’s journey began with a common complaint: travel-related insomnia. Initially using Ambien, her physician eventually switched her to Klonopin, suggesting it was a "safer" or more appropriate alternative. At the time, Zaritsky was entering menopause. "I didn’t ask any questions—a big mistake," she recalls. "I thought she was giving me something non-addictive."
The Physical Collapse (2015-2019)
As menopause progressed, Zaritsky’s health began to deteriorate mysteriously. She suffered from severe, debilitating digestive issues that led to multiple Emergency Room visits and thousands of dollars spent on naturopathic consultations. Unbeknownst to her, she was in "tolerance," a state where the body requires more of the drug to function, and the "inter-dose withdrawal" was manifesting as physical pain.
The epiphany came by accident. After taking a Xanax (another benzodiazepine) for acute pain, her stomach issues vanished instantly. When she asked her doctor for more, the doctor replied, "I can’t do that. You’re on a benzo." This was the first time Zaritsky realized the class of drug she had been taking for years.
The Rehab Disaster and Poly-drugging
Seeking a way out, Zaritsky entered a drug rehabilitation facility. This move, she warns, was a catastrophic error. The facility "cold-turkeyed" her off the Klonopin in just four days—a practice now widely condemned by withdrawal advocates for its potential to cause long-term neurological injury. To manage the resulting terror and insomnia, clinicians layered on Zoloft (an SSRI), Gabapentin (an anticonvulsant), and Zyprexa (an antipsychotic). She left the facility in a state of "protracted injury," more medicated than when she arrived.
The Spiritual and Physical Rebirth (2020-Present)
The subsequent years were defined by a "protracted withdrawal injury." Zaritsky describes a state of "adrenaline loops" and "terror" that made life nearly unbearable. However, she eventually found a path forward through a combination of brain retraining programs (such as DNRS and Primal Trust), restorative yoga, and meditation.
Crucially, she discovered the work of Dr. Mark Horowitz and the concept of "hyperbolic tapering." Today, Zaritsky is successfully and slowly tapering off her remaining medications while living a "full, joyful life" in Boise, Idaho.
Supporting Data: The Risks for the Aging Population
Zaritsky’s story is backed by a growing body of medical literature highlighting the risks of benzodiazepines in older adults. The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, maintained by the American Geriatrics Society, has long warned against the use of benzodiazepines in seniors due to:
- Increased Risk of Falls and Fractures: Impaired motor coordination.
- Cognitive Impairment: Symptoms that can mimic or exacerbate dementia.
- Respiratory Depression: Particularly when combined with other medications.
Furthermore, research published in The Lancet Psychiatry by Dr. Mark Horowitz and Professor David Taylor has validated the "hyperbolic" method of tapering. Their data shows that because drug-receptor occupancy follows a hyperbolic curve, the final stages of a taper are the most sensitive. Reducing a dose from 1mg to 0.5mg has a much smaller biological impact than reducing it from 0.5mg to zero. This scientific reality explains why many patients, like Zaritsky, fail traditional "linear" tapers (e.g., reducing by 10% of the original dose every week).
Official Responses and the Lack of Informed Consent
A recurring theme in Zaritsky’s testimony is the total absence of "informed consent." She was never told Klonopin was a benzodiazepine, nor was she warned about the difficulty of cessation.
While the FDA issued a "Boxed Warning" in 2020 for all benzodiazepines—highlighting the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions—advocates argue this information is not trickling down to the primary care level where menopause is managed.
In the therapeutic community, the response remains mixed. Zaritsky notes that when she shares her story in professional therapist forums, it is often met with silence or disinterest. "There’s no interest," she says. "We get no training about [medication withdrawal], but we are on the front lines." This gap in professional education means that many therapists may misinterpret a patient’s withdrawal symptoms as a "relapse" of their original anxiety or depression, leading to further over-medication.
Implications: Changing the Paradigm of Aging
The implications of Zaritsky’s journey extend far beyond individual recovery; they challenge the Western medical paradigm of "aging-as-a-disease."
1. Redefining Menopause Management
Zaritsky suggests that the medical community must stop reaching for psychotropics as a first-line response to menopausal transitions. She advocates for exploring Hormone Replacement Therapy (HRT) or lifestyle interventions before altering brain chemistry with benzodiazepines or SSRIs.
2. The "Unmedicated Death"
In one of the most poignant moments of the interview, Zaritsky speaks to her desire to "meet death unmedicated." This philosophy stands in stark contrast to the standard palliative care model, which often utilizes benzodiazepines heavily in the final stages of life. For Zaritsky, the quest for "radiance and joy" in her later years is inextricably linked to having a clear, un-muffled consciousness.
3. Professional Accountability
As a therapist, Zaritsky has changed how she practices. She now asks "way more questions" when clients discuss starting medication. She views it as her duty to provide the informed consent that the medical system often fails to deliver. "I would feel neglectful if a client was starting a med and they had any experience like mine… This is horrific stuff."
4. Hope for the "Too Late" Generation
Perhaps most importantly, Zaritsky’s recovery debunks the myth that the aging brain is too "fixed" to heal from chemical dependency. To those in their 60s or 70s who feel "it’s too late," she offers her own vibrant health as evidence to the contrary. "We’re never too old. It’s never too late if you want it."
Conclusion
Marsha Zaritsky’s story is a call to action for both the medical community and the aging population. It exposes a systemic failure to protect women during one of their most vulnerable biological transitions and highlights the desperate need for specialized withdrawal support. As she continues her hyperbolic taper—a process she expects will take several more years—Zaritsky stands as a testament to the possibility of reclaiming one’s "self-energy" from the fog of over-prescription.
For those seeking to follow her journey or find similar resources, Zaritsky remains active on Instagram under the handle @gracefullyunmedicatingme, where she continues to advocate for a future where aging is met with presence, rather than prescriptions.
This report was based on an interview conducted by Mad in America. MIA Reports are supported by grants from Open Excellence and donations from readers committed to transparency in the mental health system.
